Company Profile

Equator Therapeutics Inc
Profile last edited on: 5/26/2023      CAGE: 8GZH1      UEI: ECUUHHN4LUB8

Business Identifier: Enabling pharmacological stimulation of thermogenesis to achieve sustained weight loss
Year Founded
2020
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

221A Weill Hall
Berkeley, CA 94720
   N/A
   N/A
   equatortherapeutics.com/
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

With obesity and type 2 diabetes now having reached epidemic proportions, Equator Therapeutics is addressing development of a very different approach to weight loss that is designed to increase metabolism and to burn calories without exercise. Addressing the root cause of metabolic disorders – the imbalance between caloric intake and expenditure - Equator's approach is instead target mitochondria (the powerhouse of the cell) to generate heat -- an approach that has been proven to fully reverse obesity and type 2 diabetes in animals. Therapeutic application for humans was previously ineffective since mitochondrial heat production could only be induced by highly artificial methods with side effects. This recently changed with a breakthrough discovery of the protein that mitochondria naturally use to generate heat. Principals of Equator havenow developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $340,882
Project Title: New Generation of Mitochondrial Uncouplers for the Treatment of Metabolic DIsorders

Key People / Management

  Jonah Sinick -- Co-Founder, CEO

  Liliya Gabelev Khasin -- Co-Founder and Senior Scientist

  Sasha Igdari -- Director of Preclinical Development

  Yuriy Kirichok -- Co-founder, Head of Researc

  Gabelev Khasin Liliya

  Juni Suzuki -- Director, Japan branch

  Katherine Widdowson -- Head of Medicinal Chemistry

Company News

There are no news available.